Heart Failure

Vanderbilt scientists have discovered that a certain enzyme plays a crucial role in preventing obesity-related cardiac dysfunction. Read More

When buying and selling real estate, how often have you heard the realtor’s mantra — location, location, location? This is also the central theme of a recently released journal report on factors that can predict heart failure risk. Read More

Heart failure is more prevalent in the South. Here’s what you need to know. Read More

The first large study to report that HIV-infected people have a significantly higher risk of heart failure in the antiretroviral therapy era has been published in JAMA Cardiology. Read More

A new computer algorithm developed at Vanderbilt could save billions of dollars in health care costs by identifying patients at risk for readmission after being hospitalized for heart failure. Read More

Vanderbilt researchers have identified biomarkers that could be useful for evaluating and treating pregnancy-related heart failure. Read More

On April 7, a 48-year-old man from Bethpage, Tennessee, became the 300th person to receive a left ventricular assist device (LVAD) at Vanderbilt Heart and Vascular Institute (VHVI). Read More

A signaling factor called Wnt10b is a novel target for optimizing cardiac repair after a heart attack. Read More

For patients with heart failure, changes in pulmonary artery (PA) pressures are an early indication that their condition is worsening, even before they notice symptoms such as shortness of breath or weight gain. Read More

With support from a three-year, $2 million research grant from Patient-Centered Outcomes Research Institute (PCORI), Vanderbilt University Medical Center and the American Heart Association are teaming up to study heart failure care in the Emergency Department. Read More

Vanderbilt’s Department of Cardiac Surgery has developed an Advanced Heart Failure Clinical and Translational Research Group that serves as a central research resource for advanced heart failure surgeons and cardiologists. Read More

Vanderbilt University Medical Center and Acorda Therapeutics Inc. released findings from a Phase 1 clinical trial of glial growth factor 2 (GGF2) last week at the American College of Cardiology Annual Scientific Session in San Francisco. Read More

The main antioxidant compound in green tea increases contractile force in isolated heart cells, suggesting it may be useful in heart failure. Read More

Under the direction of cardiologist Rebecca Hung, M.D., Vanderbilt Heart and Vascular Institute is offering advanced heart failure services at its Columbia, Tenn., office. Read More

Levels of the protein NGAL may be a good predictor of worsening kidney function in patients with acute heart failure. Read More

Mouzon Siddiqi, who has accrued 11 months of sick leave during her 37 years as a Vanderbilt employee, has to use some of those days after suffering a cardiac arrest on Sept. 6, outside the University Club. Read More

The Health Care Innovation Award from the Centers for Medicare and Medicaid Services (CMS) is one of the largest federal research grants awarded to VUMC investigators. The funding will support the implementation and evaluation of MyHealthTeam, a model of team-based care that couples collaborative health care teams with health information technology in order to improve control of chronic conditions. Read More

A new screening tool – using glowing fish embryos – could identify therapeutics for myocardial hypertrophy and heart failure. Read More

Managing myocardial infarction – and the resulting heart failure – remains a clinical challenge. To search for chemicals that can stimulate cardiac muscle cell production, Vanderbilt Institute of Chemical Biology investigators led by Tao Zhong, Ph.D., Terri Ni, Ph.D., and Eric Rellinger, M.D., turned to a novel drug discovery tool:… Read More

A new implantable device currently being studied gives heart failure patients the ability to monitor their heart and take action when their condition begins to worsen. Read More